Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Med Genet. Aug 27, 2015; 5(3): 28-45
Published online Aug 27, 2015. doi: 10.5496/wjmg.v5.i3.28
Published online Aug 27, 2015. doi: 10.5496/wjmg.v5.i3.28
Adeno-associated virus vectors for human gene therapy
Haifeng Chen, Virovek Incorporation, Hayward, CA 94545, United States
Author contributions: Chen H solely contributed to this paper.
Conflict-of-interest statement: Haifeng Chen is the Chiefe Executive Officer and owns stocks and/or shares in Virovek Incorporation.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Haifeng Chen, PhD, CEO of Virovek Incorporation, 3521 Investment Blvd., Suite 1, Hayward, CA 94545, United States. haifengchen05@yahoo.com
Telephone: +1-510-8877121 Fax: +1-510-8877178
Received: January 8, 2015
Peer-review started: January 8, 2015
First decision: February 6, 2015
Revised: May 11, 2015
Accepted: May 16, 2015
Article in press: May 18, 2015
Published online: August 27, 2015
Peer-review started: January 8, 2015
First decision: February 6, 2015
Revised: May 11, 2015
Accepted: May 16, 2015
Article in press: May 18, 2015
Published online: August 27, 2015
Core Tip
Core tip: Adeno-associated virus (AAV) has become the first gene therapy drug approved by the Western world and spurred huge excitement in the gene therapy field. The gene therapy community is forging ahead with cautious optimism despite some challenges down the road. A battery of more than 100 AAV serotypes and variants are available and AAV production and purification technologies have become well established. Several clinical trials with AAV vectors have yielded exciting results. This paper will give you the information needed to understand the current development of the gene therapy field with AAV vectors.